Subclinical generation of acyclovir-resistant herpes simplex virus with mutation of homopolymeric guanosine strings during acyclovir therapy

Journal of Dermatological Science

Volumn 82, Issue 3, 2016, Pages 160-165

  Daikoku, Tohru ^a   Tannai, Hidenori ^a   Honda, Mariko ^b   Onoe, Tomohiko ^b   Matsuo, Koma ^b   Onoye, Yasuhiko ^c   Nishizawa, Mika ^d   Kawana, Takashi ^d   Okuda, Tomoko ^a   Hasegawa, Tomomi ^a   Shiraki, Kimiyasu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Miyamoto Cho Clinic   (Japan)

^d TEIKYO UNIVERSITY   (Japan)

Author keywords

Acyclovir; G string mutation; Herpes simplex virus; Suppressive therapy; Susceptibility; Thymidine kinase

Indexed keywords

ACICLOVIR; GUANOSINE; THYMIDINE KINASE; ANTIVIRUS AGENT; VIRAL PROTEIN;

ADULT; AGED; ARTICLE; CASE REPORT; CYTOPATHOGENIC EFFECT; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS STRAIN; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETICS; HERPES GENITALIS; HERPES SIMPLEX VIRUS 2; ISOLATION AND PURIFICATION; JAPAN; MIDDLE AGED; MUTATION; PHYSIOLOGY; VIROLOGY; YOUNG ADULT;

ACYCLOVIR; ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GUANOSINE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; JAPAN; MALE; MIDDLE AGED; MUTATION; THYMIDINE KINASE; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84964337072     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2016.02.006     Document Type: Article

References (20)

1. Hasegawa T., Kawana T., Okuda T., Horii M., Tsukada T., Shiraki K. Susceptibility to ACV of herpes simplex virus isolates obtained between 1977 and 1996 in Japan. J. Med. Virol. 2001, 63:57-63.
2. Reyes M., Shaik N.S., Graber J.M., Nisenbaum R., Wetherall N.T., Fukuda K., et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch. Intern. Med. 2003, 163:76-80.
3. Honda M., Okuda T., Hasegawa T., Kurokawa M., Shiraki K., Matsuo K., et al. Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of acyclovir resistance of herpes simplex virus type 2. Antivir. Chem. Chemother. 2001, 12:233-239.
4. Baker D.A. Long-term suppressive therapy with acyclovir for recurrent genital herpes. J. Int. Med. Res. 1994, 22(Suppl. 1):24A-31A. Discussion 31A-32A.
5. Reitano M., Tyring S., Lang W., Thoming C., Worm A.M., Borelli S., et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV study group. J. Infect. Dis. 1998, 178:603-610.
6. Leung D.T., Sacks S.L. Current recommendations for the treatment of genital herpes. Drugs 2000, 60:1329-1352.
7. Brantley J.S., Hicks L., Sra K., Tyring S.K. Valacyclovir for the treatment of genital herpes. Expert Rev. Anti-Infect. ther. 2006, 4:367-376.
8. Hussin A., Md Nor N.S., Ibrahim N. Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1. Antiviral Res. 2013, 100:306-313.
9. Talarico C.L., Phelps W.C., Biron K.K. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J. Virol. 1993, 67:1024-1033.
10. Ida M., Kageyama S., Sato H., Kamiyama T., Yamamura J., Kurokawa M., et al. Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antiviral Res. 1999, 40:155-166.
11. Shimada Y., Suzuki M., Shirasaki F., Saito E., Sogo K., Hasegawa M., et al. Genital herpes due to acyclovir-sensitive herpes simplex virus caused secondary and recurrent herpetic whitlows due to thymidine kinase-deficient/temperature-sensitive virus. J. Med. Virol. 2007, 79:1731-1740.
12. Okuda T., Kurokawa M., Matsuo K., Honda M., Niimura M., Shiraki K. Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus. J. Med. Virol. 2004, 72:112-120.
13. Hasegawa T., Kurokawa M., Yukawa T.A., Horii M., Shiraki K. Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV. Antiviral Res. 1995, 27:271-279.
14. Kurokawa M., Hozumi T., Tsurita M., Kadota S., Namba T., Shiraki K. Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo. J. Pharmacol. Exp. Ther. 2001, 297:372-379.
15. Kurokawa M., Ochiai H., Nagasaka K., Neki M., Xu H., Kadota S., et al. Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Res. 1993, 22:175-188.
16. Kurokawa M., Basnet P., Ohsugi M., Hozumi T., Kadota S., Namba T., et al. Anti-herpes simplex virus activity of moronic acid purified from Rhus javanica in vitro and in vivo. J. Pharmacol. Exp. Ther. 1999, 289:72-78.
17. Frobert E., Burrel S., Ducastelle-Lepretre S., Billaud G., Ader F., Casalegno J.S., et al. Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France. Antiviral Res. 2014, 111:36-41.
18. Coen D.M., Schaffer P.A., Furman P.A., Keller P.M., St Clair M.H. Biochemical and genetic analysis of acyclovir-resistant mutants of herpes simplex virus type 1. Am. J. Med. 1982, 73:351-360.
19. Parris D.S., Harrington J.E. Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates. Antimicrob. Agents Chemother. 1982, 22:71-77.
20. Kost R.G., Hill E.L., Tigges M., Straus S.E. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N. Engl. J. Med. 1993, 329:1777-1782.